Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 8;39(11):1445-1447.
doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12.

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Duncan R McKenzie  1 , Miguel Muñoz-Ruiz  1 , Leticia Monin  1 , Thanussuyah Alaguthurai  2 , Thomas Lechmere  3 , Sultan Abdul-Jawad  4 , Carl Graham  3 , Emily Pollock  5 , Rosalind Graham  4 , Kamila Sychowska  5 , Jeffrey Seow  3 , Catherine Tremain  6 , Charalampos Gousis  6 , Clara Domingo-Vila  5 , Jack Cooper  6 , Jennifer Vidler  7 , Kasia Owczarczyk  6 , Angela Swampillai  8 , Hartmut Kristeleit  6 , Michael H Malim  3 , Paul Fields  9 , Piers E M Patten  10 , Sophie Papa  9 , Bernard V North  11 , Timothy Tree  5 , Katie J Doores  3 , Adrian C Hayday  12 , Sheeba Irshad  13
Affiliations

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

Duncan R McKenzie et al. Cancer Cell. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

    1. Abdul-Jawad S., Baù L., Alaguthurai T., Del Molino Del Barrio I., Laing A.G., Hayday T.S., Monin L., Muñoz-Ruiz M., McDonald L., Francos Quijorna I., et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021;39:257–275.e6. - PMC - PubMed
    1. Addeo A., Shah P.K., Bordry N., Hudson R.D., Albracht B., Di Marco M., Kaklamani V., Dietrich P.Y., Taylor B.S., Simand P.F., et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39:1091–1098.e2. - PMC - PubMed
    1. Bakouny Z., Hawley J.E., Choueiri T.K., Peters S., Rini B.I., Warner J.L., Painter C.A. COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell. 2020;38:629–646. - PMC - PubMed
    1. Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031–1033. - PMC - PubMed
    1. Monin L., Laing A.G., Muñoz-Ruiz M., McKenzie D.R., Del Molino Del Barrio I., Alaguthurai T., Domingo-Vila C., Hayday T.S., Graham C., Seow J., et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–778. - PMC - PubMed

MeSH terms